Cadila Pharmaceuticals has launched the obetocad in India, a generic version of Ocaliva (obeticholic acid) primarily used for the treatment of primary biliary cholangitis (PBC).
Obetocad is available in 5 mg and 10 mg tablets in packs of 10 tablets. It is also US FDA and EMA approved and recently received its DCGI approvals. obetocad also has the potential to be used in other indications such as NASH, NAFLD, severe acute hepatitis, bile acid diarrhoea, bariatric and gallstone diseases.
For the treatment of PBC, currently, ursodeoxycholic acid (UDCA) is being extensively used. Around 40% of the patients do not respond to UDCA treatment and 5-10% of patients observe severe side effects. Obetocad can be used as a monotherapy or along with UDCA for the treatment of patients who are unresponsive to UDCA therapy.
“There is an unmet need in the treatment of PBC. ursodeoxycholic acid is the only approved standard of care but a major chunk of the patients do not respond to the treatment. Obetocad containing obetocholic acid is now DCGI approved and shows positive results in patients. This generic drug is launched for the first time in the country, and with obetocad, we hope to provide an option to all the patients of PBC” shared Narendra Deode, vice president, Cadila Pharmaceuticals.
“With the launch of every product, we strengthen our core philosophy of providing quality medicines to all. With obetocad, we plan to provide a quality solution to the patients of PBC who do not get relief from other standard therapy options. We are constantly working towards finding the next innovative drug for our patients,” said O P Singh, president -sales and marketing, Cadila Pharmaceuticals Limited.
Cadila Pharmaceuticals has always been focused on making sure high quality, affordable, and life-saving treatments are within the reach of patients. Recently, Sepsivac an innovative drug from Cadila Pharma received the pharma excellence award for being the most promising drug in the fight against COVID-19. Cadila Pharma has also recently launched 4 biosimilar products in the past 2 months under the brand name Bevaro, Ritucad, Cadalimab, and NuPTH for the treatment of cancer and osteoporosis. Cadila plans to launch multiple biosimilar products this year for the Indian market.